Education
About Us
Working with TipRanks
Follow Us
Resmed (RMD)
NYSE:RMD
RMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$199.92 - $293.81
Previous CloseN/A
Volume178.41K
Average Volume (3M)1.09M
Market Cap
$40.19B
Enterprise Value$37.56B
Total Cash (Recent Filing)$1.21B
Total Debt (Recent Filing)$882.32M
Price to Earnings (P/E)29.0
Beta0.95
Next Earnings
Oct 23, 2025EPS Estimate
2.52Last Dividend Ex-Date
Aug 14, 2025Dividend Yield0.8%
Share Statistics
EPS (TTM)2.55
Shares Outstanding146,414,840
10 Day Avg. Volume910,052
30 Day Avg. Volume1,091,885
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue7.30
Enterprise Value/Gross Profit12.30
Enterprise Value/Ebitda19.53
Forecast
1Y Price Target
$302.89Price Target Upside10.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Bulls Say, Bears Say
Bulls Say
Growth OpportunitiesManagement is confident that GLP-1 drugs will ultimately be a tailwind to ResMed's growth.
Market PerformanceRMD exceeded expectations with revenue and earnings per share beat across all segments.
Bears Say
Growth ChallengesOrganic revenue growth slowed to 8.6% organic in F4Q25 from 8.9% organic in F3Q25 and this marked the third consecutive quarter of slowing organic growth.
Market CompetitionRMD is facing increasing competition from both neuromodulation devices and drugs.
Resmed News
RMD FAQ
What was Resmed’s price range in the past 12 months?
Resmed lowest stock price was $199.92 and its highest was $293.81 in the past 12 months.
What is Resmed’s market cap?
Resmed’s market cap is $40.19B.
When is Resmed’s upcoming earnings report date?
Resmed’s upcoming earnings report date is Oct 23, 2025 which is in 53 days.
How were Resmed’s earnings last quarter?
Resmed released its earnings results on Jul 31, 2025. The company reported $2.55 earnings per share for the quarter, the consensus estimate of $2.55 by $0.
Is Resmed overvalued?
According to Wall Street analysts Resmed’s price is currently Undervalued.
Does Resmed pay dividends?
Resmed pays a Quarterly dividend of $0.6 which represents an annual dividend yield of 0.8%. See more information on Resmed dividends here
What is Resmed’s EPS estimate?
Resmed’s EPS estimate is 2.52.
How many shares outstanding does Resmed have?
Resmed has 146,414,840 shares outstanding.
What happened to Resmed’s price movement after its last earnings report?
Resmed reported an EPS of $2.55 in its last earnings report, expectations of $2.55. Following the earnings report the stock price went up 2.672%.
Which hedge fund is a major shareholder of Resmed?
Currently, no hedge funds are holding shares in RMD
Resmed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$302.89 (10.34% Upside)
$302.89 (10.34% Upside)
Blogger Sentiment
Bullish
RMD Sentiment 90%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 96.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $739.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.87%
12-Months-Change
Fundamentals
Return on Equity
25.86%
Trailing 12-Months
Asset Growth
18.95%
Trailing 12-Months
Company Description
Resmed
ResMed Inc. (RMD) is a global leader in digital health and cloud-connected devices, primarily focused on developing innovative solutions for people with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic respiratory conditions. Founded in 1989, the company operates in two main sectors: the Sleep and Respiratory Care segment, which includes devices and software for managing sleep disorders and respiratory conditions, and the Software as a Service (SaaS) segment, which provides cloud-connected platforms for healthcare providers to monitor and manage patient care effectively.
RMD Company Deck
RMD Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance for ResMed in Q4 FY 2025, with significant achievements in revenue growth, gross margin expansion, and innovation investments. Despite potential challenges from competitive bidding and some market-specific issues, particularly in China, the overall sentiment of the call was positive.View all RMD earnings summariesRMD Revenue Breakdown
87.54% Sleep and Respiratory Care
12.46% Residential Care Software
RMD Stock 12 Month Forecast
Average Price Target
$302.89
▲(10.34% Upside)
Technical Analysis
Baxter International
―
Becton Dickinson
―
Hologic
―
Masimo
―
West Pharmaceutical Services
―
Ownership Overview
0.51% Insiders
17.35% Mutual Funds
8.81% Other Institutional Investors
48.55% Public Companies and
Individual Investors